{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-047220","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.087760+00:00","generated_at":"2026-05-24T01:48:51.908919+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Jaguar Health 2024 revenue $11.7M, up 20% YoY; net loss narrows to $38.5M","bullets":["2024 net revenue of ~$11.7M (prescription+non-prescription+license) increased ~20% from $9.8M in 2023.","Q4 2024 revenue of ~$3.5M rose 13% sequentially and 53% YoY; Mytesi prescription volume up 3.9% in 2024.","Net loss attributable to common shareholders improved to $38.5M from $41.3M in 2023; R&D spend fell $2.1M to $16.5M.","Expects first proof-of-concept results in Q2 2025 for crofelemer in short bowel syndrome and microvillus inclusion disease trials.","FDA meeting scheduled Q2 2025 to discuss Phase 3 OnTarget trial results in breast cancer subgroup."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-047220","json":"https://secwatch.observer/filing/0000950170-25-047220.json","markdown":"https://secwatch.observer/filing/0000950170-25-047220.md","text":"https://secwatch.observer/filing/0000950170-25-047220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000095017025047220/0000950170-25-047220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000095017025047220/jagx-20250331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:48:51.908919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}